LOUISVILLE, Ky.--(BUSINESS WIRE)--Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has signed an exclusive license to develop and market 4-IPP and its related compounds, discovered by scientists at the University of Louisville’s James Graham Brown Cancer Center (Brown Cancer Center).
